Depuis la recherche translationnelle jusqu’aux nouveaux paradigmes thérapeutiques : mise à jour des données dans les chordomes
- 24 December 2019
- journal article
- review article
- Published by Elsevier BV in Bulletin du Cancer
- Vol. 107 (1), 129-135
- https://doi.org/10.1016/j.bulcan.2019.10.008
Abstract
No abstract availableKeywords
This publication has 52 references indexed in Scilit:
- Multidisciplinary Management of Recurrent ChordomasCurrent Treatment Options in Oncology, 2013
- Converging paths to progress for skull base chordoma: Review of current therapy and future molecular targetsSurgical Neurology International, 2013
- Does insulin‐like growth factor 1 receptor (IGF‐1R) targeting provide new treatment options for chordomas? A retrospective clinical and immunohistochemical studyHistopathology, 2012
- The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic targetThe Journal of Pathology, 2010
- Response to erlotinib in a patient with treatment refractory chordomaAnti-Cancer Drugs, 2009
- T (brachyury) gene duplication confers major susceptibility to familial chordomaNature Genetics, 2009
- Potential therapeutic targets for chordoma: PI3K/AKT/TSC1/TSC2/mTOR pathwayBritish Journal of Cancer, 2009
- Risk Factors for Blood Loss During Sacral Tumor ResectionClinical Orthopaedics and Related Research, 2008
- Frequent deletion of the CDKN2A locus in chordoma: analysis of chromosomal imbalances using array comparative genomic hybridisationBritish Journal of Cancer, 2007
- Level-adjusted perioperative risk of sacral amputationsJournal of Surgical Oncology, 2006